Portal de Periódicos da CAPES

Anthelmintics for dogs and cats

1987; Elsevier BV; Volume: 17; Issue: 2 Linguagem: Inglês

10.1016/0020-7519(87)90127-5

1879-0135

D. Ε. Jacobs,

Parasite Biology and Host Interactions

Abstract As the dog and cat anthelmintic market is small, fragmented and dominated by old-fashioned narrow spectrum products, there is little incentive for the pharmaceutical companies to invest major research resources in this area. Development of new products will always be of relatively low priority and progress will be much slower than is the case with ruminant anthelmintics. Some successes since ICOPA V can however be claimed. The previously reported cesticidal properties of praziquantel have been put to good use and have contributed to the progress made in many hydatid control programmes. Ivermectin shows promise as an alternative heartworm prophylactic and the applications for multiple dose therapy with the benzimidazoles continue to increase. In the latter case, much still needs to be done to explore the full potential of this chemical group and to define optimum dosage regimes for both broad spectrum therapy and for the prophylaxis of T. cati and A. caninum infections. It is to be hoped that the increasing awareness of the general public concerning the role of worm control in the broader concept of responsible pet ownership will create a greater demand for expert advice and more effective chemotherapy.